36C24426N0403↗
Exelan Pharmaceuticals Inc received this contract from 244-Network Contract Office 4 (36C244), Department of Veterans Affairs: $779.5K obligated so far for drugs and biologicals. Its period of performance ended 2026-09-18.
Key facts · data as of Oct 25, 2026
- Recipient
- Exelan Pharmaceuticals Inc
- Awarding agency
- Department of Veterans Affairs
- Contracting office
- 244-Network Contract Office 4 (36C244) (36C244)
- Obligated to date
- $779.5K
- Potential value
- $786.1K
- Ends
- 2026-09-18
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 36C24426N0403, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_36C24426N0403_3600_36F79720D0227_3600
Exelan Pharmaceuticals Inc: all federal awards · Department of Veterans Affairs: spending · 244-Network Contract Office 4 (36C244): what it buys · The follow-on: recompete brief
SPECIALTY PHARMACEUTICALS LENALIDOMIDE
Up for re-bid: ends 2026-09-18. Recompete brief → · 6505--Lab Supplies - Radiopharm Philadelphia VA Medical Center ↗
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Pharmaceutical Preparation Manufacturing (NAICS 325412)
- Contracting office
- 244-Network Contract Office 4 (36C244) (36C244)
- Competition
- Full and open competition · 2 offers received
- Pricing
- Firm fixed price
- How it was bought
- GSA Schedule · under 36F79720D0227
- Where the work is
- CAN
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
2 actions since 2026-02-06. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-18 | P00001 | Supplemental agreement (work within scope) | -$1.41M | SPECIALTY PHARMACEUTICALS LENALIDOMIDE |
| 2026-02-06 | 0 | $2.19M | SPECIALTY PHARMACEUTICALS LENALIDOMIDE |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗